Lymphoma Clinical Studies

Some of the many Hematology/Oncology research opportunities available related to lymphoma are listed below. Select a study to review a brief description and requirements. Parents or guardians of children who might be eligible are encouraged to inquire about enrollment. Contact information is provided at the end of each study.

Please note that Pilot and Phase I studies are the most experimental and should be considered only after other treatments or trials have been attempted without success.

Thank you for exploring these opportunities and helping us to find cures and prevent childhood disease.

Clinical Studies

Researchers

Acute Lymphoblastic Leukemia and B-Lineage Lymphoma Treatment via Risk-Adapted Chemotherapy – Phase III

Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk B-Acute Lymphoblastic Leukemia or localized B-Lineage Lymphoblastic Lymphoma

Read more

Hodgkin Lymphoma Treatment with Brentuximab Vendotin and Gemcitabine – Phase I/II

Brentuximab Vedotin in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma

Read more

M0 Medulloblastoma Treatment in Very Young Children – Phase I

Study of Eribulin Mesylate, a Novel Microtubule Targeting Chemotherapeutic Agent, in Children with Refractory or Recurrent Solid Tumors including Lymphomas

Read more

Non-Hodgkin Lymphoma or B-Cell Leukemia Evaluation of Rituximab– Phase II/III

Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma or Mature B-cell Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Read more

Solid Tumor and Lymphoma Treatment with PF-02341066 – Phases I and II

PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

Read more

Solid Tumor or ALCL Treatment with Crizotinib and Conventional Chemotherapy – Phase I

Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Read more

T-cell Lymphoblastic Leukemia and Lymphoma Treatment with Bortezomib – Phase III

Bortezomib on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Read more

Linda M. McAllister-Lucas, MD, PhD

Read more

Cheryl A Hillery, MD

Read more

Debra E. Cohen, MD

Read more

James D Cooper, MD

Read more

Melvin Deutsch, MD

Read more

Erika Dawn Friehling, MD

Read more

James Anthony Graves, PhD, MD

Read more

Lynn M Malec, MD

Read more

Scott H Maurer, MD

Read more

Linda M. McAllister-Lucas, MD, PhD

Read more

Amma Twumwa Owusu-Ansah, MD

Read more

Edward V. Prochownik, MD, PhD

Read more

A. Kim Ritchey, MD

Read more

Jean M. Tersak, MD

Read more

Randy M Windreich, MD

Read more

Michael R. Wollman, MD

Read more